Redeye reduces its Base Case slightly despite cutting its 2024-2025 EBIT forecasts following a soft ...
Adj. EBITA in line, we expect higher margins ahead Minor revisions: adj.
Highest order intake in company's history We lift '24e-'26e EBIT by 14% on higher sales and GMs EBIT...
Redeye repeats its view on Sedana Medical’s 2024 sales growth target to be conservative, as is demon...
- Gross margin est. down on continually elevated freight rates - '24e-'26e EBITA down 4-2% - '24e-'2...
- '24e sales up 2% - New ARR shows sequential growth stability - '24e-'25e EV/EBITDA ~11-9x Another ...
Redeye comments on Thunderful Group’s divestment of the distribution company of gaming hardware, cal...
AVTECH’s net sales and EBITDA were below Redeye Research estimates (RRe), but the company managed to...
Redeye returns with a research update on Alzecure following its Q1 report and recent events in the c...
Redeye states that the report aligns with preannounced figures and is slightly below RRe on net sale...
DT’s Q1 didn’t contain many surprises other than MBU being weaker and SBU stronger than expected.
Mangold Insight inleder bevakning av medicinteknik-bolaget Prolight Diagnostics med rekommendationen...
Exel’s Q1 results remained quite weak, although q/q improvement continued.
Dovre Q1 EBIT, excluding the write-off, was a bit below our estimate but we raise our Renewable Ener...
Redeye comments on yesterday’s news where Tessin has secured additional funding by issuing a convert...
Redeye is happy to see solid Q1 numbers including 80% higher order intake Y/Y.
Redeye provides a brief comment on Artificial Solutions' Q1 2024 report, which closely aligns with o...
We lower '24e-'26e adj. EBITA by 35-1% Potential for utilisation improvement in H2'24 '24e-'25e EV/E...
Adj. EBITA SEK 27.3m (-1% vs. ABGSCe 27.6m) Q1 numbers imply no material estimate revisions Trading ...